PAKAFYT 200MG TAB 10s

Pakafyt tablets for oral administration contain sotagliflozin, a sodium-glucose
cotransporter 2 (SGLT2) inhibitor. It lowers blood glucose (blood sugar) levels.
Sotagliflozin works by slowing and reducing the absorption of glucose from
food, and by increasing the amount of glucose that is passed out in urine.
Together, these actions help to lower the increased amount of glucose in the
blood that occurs in patients with diabetes.
USES:
It is indicated for use in adults to reduce the risk of
• Cardiovascular Death
• Hospitalization for heart failure
• Urgent heart failure visit in adults with
a. Heart Failure
b. Cardiovascular risk factors
c. Chronic Kidney Disease
d. Type 2 Diabetes Mellitu

BENEFITS:
• Reduced heart failure hospitalization
• Reduced cardiovascular death risks
• Improved left ventricular ejection fraction & function
• Reduced atherosclerosis progression (anti-inflammatory, lipid-lowering
effects)
• Lower blood pressure
• Reduced arrhythmia risk
• Reduced risks of kidney failure
• Improved glycemic control (HbA1c reduction)
• Improved exercise capacity and quality of life.

SIDE EFFECTS:
• Urinary Tract Infection
• Dehydration
• Diarrhea
• Low Blood Sugar Levels